ft 23 mar 94 survey pharmaceut 10 thorough prepar cut cost manufactur product save year develop could equival final year sale lead compound could dollar 400m clinic trial industri oper stringent regulatori control pharmaceut industri complex volum regul indic high cost area one clinic trial expens time consum three phase clinic research longest costli stage develop new drug take averag four six year although depend type drug may extrem case requir 10 year singl advanc effici commerci scientif benefici consider data assembl trial subject detail statist evalu medic interpret effect inform technolog manag competit aid cut high cost help streamlin product develop approv process compani cannot take short cut clinic trial well plan risk error document test greatli reduc today increas number world lead pharmaceut compani look contract research organis cro run part case whole packag clinic trial dr john mill intern vice presid besselaar one largest cro worldwid said dramat increas amount contract clinic trial past coupl year twice number propos say dr mill compani request part servic other request full work add measur much clinic trial cost highlight prof richard peto clinic trial servic unit radcliff infirmari oxford carri signific trial 20 000 peopl effect cholesterol lower drug trial cost pound 20m equal sponsor roch merck mrc larg sum view proport pound 20m sale drug dollar 1bn per year ask prof peto accord spokesman us pharmaceut manufactur associ clinic trial us cost dollar 35 000 per patient six month period altern clinic trial 1989 us congress creat agenc health care polici research ahcpr comb vast databas record accumul hospit insur govern health programm sinc late 1980 studi known collect outcom research spend nearli dollar 200m type research ahcpr cannot point singl case databas studi chang clinic practic comment prof peto mani compani industri hope intern confer harmonis ich process save lot time money clinic trial desir japanes regulatori agenc harmonis requir europ america dr trevor jone research develop director wellcom say repeat stabil data storag shelf life one way japan though difficulti clinic side still case repeat lot clinic work japan 65 mostli clinic relat scientist japan carri necessari phase iii trial add dr jone say wellcom reorganis r amp meet global chang new group set wellcom call euroclin prelud worldclin 200 staff spread geograph across europ larg group franc group itali germani basic acquisit data done without incent tax relief three import advantag touch local clinician regul local compani say dr jone dr pierr simon research develop director sanofi observ set high standard get compound full develop look strength oral activ durat action toxicolog genotox also make sure molecul metabolis man drug clear bar even set high say dr simon organis trial like anti thrombot clopidogrel real challeng add need two year studi 500 centr 15 000 patient difficult young compani far enrol 9 000 patient far faster thought save six month huge boost revenu larg compound janoth compani keep tight rein clinic trial prepar fujisawa dr hitoshi oyasu manag director research develop divis comment like cut compound product pipelin clinic trial costli howev 18 nce cycl mani look pre clinic data clinic advantag get kill cut promis oral anti histamin last year add compani believ ich make differ futur clinic trial one day progress seem difficult moment dr oyasu say tri reduc number clinician centr use trial want focu investig reliabl deliv data time past japanes group use clinic trial part market strategi case one patient per hospit want least eight per hospit dr william scott senior vice presid exploratori drug discoveri bristol myer squibb say save one year develop equival final year sale big compound could dollar 400m comment dr scott even cost front save time worth hundr million dollar problem hurdl get higher time add regulatori process becom increasingli complex demand take fact trial use activ control compound compar new molecul old one fact regulatori author ask clinic end point rather surrog marker admittedli one counter trend area life threaten diseas avail therapi get acceler approv use surrog marker approv condit give drug requir dr scott add bm ddi gave 27 000 patient d4t gave 9 600 patient taxol also given acceler approv writer alan archer editor ft newslett pharmaceut busi news